Description

BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and CompBead to ensure that BD Comp beads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
Specifications

General

SourceMouse IFN alpha A, amino acids (Cys24 - Glu190) (Accession # NM_206870), was expressed in E. coli.
Molecular MassThe 167 amino acid recombinant protein has a predicted molecular mass of approximately 19.3 kD. The protein migrates at approximately 20 kD in DTT-reducing conditions and at approximately 17 kD in non-reducing conditions by SDS-PAGE. The predicted N-terminal amino acid is Cys.
Purity>95%, as determined by Coomassie stained SDS-PAGE.
Formulation0.22 µm filtered protein solution is in PBS, pH 7.2.
Endotoxin LevelLess than 0.01 ng per µg cytokine as determined by the LAL method.
Concentration10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & HandlingUnopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
ActivityRecombinant Mouse IFN-α induces CCL2 (MPC-1) in Raw264.7 cells in a dose dependent manner. The ED50 range for this effect is 0.04 – 0.4 µg/mL
ApplicationBioassay
Application NotesBioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected].
Product CitationsLin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed Humeau J, et al. 2020. EMBO Mol Med. 12:e11622. PubMed Holay N, et al. 2023. Front Immunol. 13:1047661. PubMed Luo H, et al. 2023. JCI Insight. 8:. PubMed Pang W, et al. 2023. iScience. 26:106579. PubMed Fukao S, et al. 2021. Elife. 10:. PubMed Xiang H, et al. 2022. Cancer Sci. 113:2513. PubMed Asano T, et al. 2022. J Clin Lipidol. 17:78. PubMed Lu YN, et al. 2021. PLoS Biol. 19:e3001096. PubMed Jiao H, et al. 2020. Nature. 580:391. PubMed Eissa IR, et al. 2021. Int J Cancer. 149:214. PubMed Li C, et al. 2021. Cell Metabolism. 33(8):1610-1623.e5. PubMed Maroun JW, et al. 2020. Mol Ther Oncolytics. 0.913888889. PubMed Ho WW, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Kalliara E, et al. 2022. Front Immunol. 13:947213. PubMed Schafer JB, et al. 2022. J Biol Chem. :102694. PubMed
StructureCytokine.
DistributionMonocytes/macrophages, fibroblasts, lymphoblastoid cells, and a variety of cell types following induction by viruses. IFN-α is also induced by nucleic acids, glucocorticoid hormones, n-butyrate, and 5-bromodeoxy uridine in different cells.
FunctionIFN-α stimulates cytotoxic T lymphocytes and natural killer cell function. IFN-α has immunomodulatory and antiviral properties.
InteractionVarieties of cells express the IFNα receptor (IFNAR).
Ligand/ReceptorIFNAR complex has two components: IFNAR1 and IFNAR2.
BioactivityCytopathic effect inhibition assay using EMC virus on L929 cells.
Biology AreaImmunology, Innate Immunity
Molecular FamilyCytokines/Chemokines
Antigen References1. Siren J, et al. 2005. J. Immunol. 174:1932. 2. Bose A, Baral R. 2007. Immunol. Lett. 108:68. 3. Zhao W, et al. 2008. J. Immunol. 180:5483. 4. Sadler AJ, Williams BR. 2008. Nat. Rev. 8:559. 5. BjorcK P, et al. 2011. J. Immunol. 186:1477. 6. Badiger R, et al. 2012. PLoS One 7:e46779. 7. Aghemo A, et al. 2010. Nat. Rev. Gastroenterol. Hepatol. 7:485. 8. Mukherjee KK, et al. 2012. Indian J. Med. Res. 136:54. 9. Becker-Merok A, et al. 2013. Lupus 22:155.
Gene ID242517
UniProtView information about IFN-alpha on UniProt.org
Regulatory StatusRUO
Other NamesMus musculus interferon alpha 15 (Ifna15), MuIFN-alpha-A, Ifnaa, IFN-alpha, IFNa, IFN-a
BD 752804 BV510 Mouse Anti-Human TCR Vβ9 AMKB1-2 | IRIGHT